However, in older children and adults with SMA, which collectively represent two-thirds of the SMA population, early gene therapy treatment is not an option, and these patients may need additional SMN-independent therapies to restore function of muscle and other tissues. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.